Original Article

You have full text access to this OnlineOpen article

African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy†

  1. Wendy A. Woodward MD, PhD1,
  2. Eugene H. Huang MD1,
  3. Marsha D. McNeese MD1,
  4. George H. Perkins MD1,
  5. Susan L. Tucker MD2,
  6. Eric A. Strom MD1,
  7. Lavinia Middleton MD3,
  8. Karin Hahn MD4,
  9. Gabriel N. Hortobagyi MD4,
  10. Thomas A. Buchholz MD1,‡,*

Article first published online: 23 OCT 2006

DOI: 10.1002/cncr.22281

Issue

Cancer

Cancer

Volume 107, Issue 11, pages 2662–2668, 1 December 2006

Additional Information

How to Cite

Woodward, W. A., Huang, E. H., McNeese, M. D., Perkins, G. H., Tucker, S. L., Strom, E. A., Middleton, L., Hahn, K., Hortobagyi, G. N. and Buchholz, T. A. (2006), African-American race is associated with a poorer overall survival rate for breast cancer patients treated with mastectomy and doxorubicin-based chemotherapy. Cancer, 107: 2662–2668. doi: 10.1002/cncr.22281

Author Information

  1. 1

    Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  2. 2

    Department of Biomathematics, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  3. 3

    Department of Pathology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  4. 4

    Department of Breast Medical Oncology, University of Texas M. D. Anderson Cancer Center, Houston, Texas

  1. ‡

    Fax: (713) 794-5579

*Department of Radiation Oncology, University of Texas M. D. Anderson Cancer Center, 1515 Holcolmbe Blvd., Unit 97, Houston, TX 77030

  1. †

    Presented at the San Antonio Breast Cancer Symposium annual meeting, San Antonio, TX, December 3ndash;6, 2003.

Publication History

  1. Issue published online: 17 NOV 2006
  2. Article first published online: 23 OCT 2006
  3. Manuscript Accepted: 30 AUG 2006
  4. Manuscript Revised: 22 AUG 2006
  5. Manuscript Received: 3 MAY 2006

Funded by

  • National Cancer Institute. Grant Numbers: CA16672, T32CA77050
  • Nellie B. Connally Breast Cancer Research Fund
  • Arlette and William Colmen Foundation
  • Stanford and Joan Alexander Foundation, Houston, Texas

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (165K)

REFERENCES

  • 1
    Society AC. American Cancer Society. Cancer facts and figures-2001. Atlanta, 2001.
  • 2
    Reis L, Kosary C, Hankey B, Miller B, Clegg L, Edwards B. SEER cancer statistics review. Bethesda, MD: National Cancer Institute, 1999: 99–2789.
  • 3
    Smigal C, Jemal A, Ward E, et al. Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin. 2006; 56: 168–183.
    Direct Link:
  • 4
    Hershman D, Weinberg M, Rosner Z, et al. Ethnic neutropenia and treatment delay in African American women undergoing chemotherapy for early-stage breast cancer. J Natl Cancer Inst. 2003; 95: 1545–1548.
  • 5
    Dignam JJ. Differences in breast cancer prognosis among African-American and Caucasian women. CA Cancer J Clin. 2000; 50: 50–64.
    Direct Link:
  • 6
    Cross CK, Harris J, Recht A. Race, socioeconomic status, and breast carcinoma in the U.S.: what have we learned from clinical studies. Cancer. 2002; 95: 1988–1999.
    Direct Link:
  • 7
    Jatoi I, Becher H, Leake CR. Widening disparity in survival between white and African-American patients with breast carcinoma treated in the U. S. Department of Defense Healthcare system. Cancer. 2003; 98: 894–899.
    Direct Link:
  • 8
    Newman LA, Griffith KA, Jatoi I, Simon MS, Crowe JP, Colditz GA. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol. 2006; 24: 1342–1349.
  • 9
    Dignam JJ, Wieand K, Johnson KA, et al. Effects of obesity and race on prognosis in lymph node-negative, estrogen receptor-negative breast cancer. Breast Cancer Res Treat. 2006; 97: 245–254.
  • 10
    Mohla S, Sampson C, Khan T, Somebody E. Estrogen and progesterone receptors in breast cancer in black Americans. Cancer. 1985; 50: 552–559.
    Direct Link:
  • 11
    Natarajan N, Nemoto T, Mettlin C, Murphy GP. Race-related differences in breast cancer patients. Results of the 1982 national survey of breast cancer by the American College of Surgeons. Cancer. 1985; 56: 1704–1709.
    Direct Link:
  • 12
    Eley JW, Hill HA, Chen VW, et al. Racial differences in survival from breast cancer. Results of the National Cancer Institute Black/White Cancer Survival Study. JAMA. 1994; 272: 947–954.
  • 13
    Li CI, Malone KE, Daling JR. Differences in breast cancer hormone receptor status and histology by race and ethnicity among women 50 years of age and older. Cancer Epidemiol Biomarkers Prev. 2002; 11: 601–607.
  • 14
    Elledge RM, Clark GM, Chamness GC, Osborne CK. Tumor biologic factors and breast cancer prognosis among white, Hispanic, and black women in the United States. J Natl Cancer Inst. 1994; 86: 705–712.
  • 15
    Middleton LP, Chen V, Perkins GH, Pinn V, Page D. Histopathology of breast cancer among African-American women. Cancer. 2003; 97(1 Suppl ): 253–257.
    Direct Link:
  • 16
    Blumenschein GR, Buzdar AU, Hortobagyi GN. FAC + BCG as adjuvant therapy in breast cancer: an 8-year update. Recent Results Cancer Res. 1984; 96: 129–132.
  • 17
    Buzdar AU, Blumenschein GR, Smith TL, et al. Adjuvant chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide, with or without Bacillus Calmette-Guerin and with or without irradiation in operable breast cancer. A prospective randomized trial. Cancer. 1984; 53: 384–389.
    Direct Link:
  • 18
    Buzdar AU, Hortobagyi GN, Marcus CE, Smith TL, Martin R, Gehan EA. Results of adjuvant chemotherapy trials in breast cancer at M. D. Anderson Hospital and Tumor Institute. NCI Monogr. 1986: 81–85.
  • 19
    Buzdar AU, Hortobagyi GN, Smith TL, et al. Adjuvant therapy of breast cancer with or without additional treatment with alternate drugs. Cancer. 1988; 62: 2098–2104.
    Direct Link:
  • 20
    Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Am J Clin Oncol. 1989; 12: 123–128.
  • 21
    Buzdar AU, Hortobagyi GN, Kau SW, et al. Adjuvant therapy with escalating doses of doxorubicin and cyclophosphamide with or without leukocyte alpha-interferon for stage II or III breast cancer. J Clin Oncol. 1992; 10: 1540–1546.
  • 22
    Theriault R, Buzdar AU, Hortobagyi GN, et al. Irradiation (XRT) following mastectomy in patients treated with FAC adjuvant therapy-MD Anderson Cancer Center experience. Paper presented at: American Society of Clinical Oncology, 1998.
  • 23
    Hortobagyi GN, Ames FC, Buzdar AU, et al. Management of stage III primary breast cancer with primary chemotherapy, surgery, and radiation therapy. Cancer. 1988; 62: 2507–2516.
    Direct Link:
  • 24
    Buzdar AU, Singletary SE, Theriault RL, et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin, and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol. 1999; 17: 3412–3417.
  • 25
    Buzdar AU, Singletary SE, Booser DJ, Frye DK, Wasaff B, Hortobagyi GN. Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience. Surg Oncol Clin N Am. 1995; 4: 715–734.
  • 26
    Koscielny S, Thames HD. Biased methods for estimating local and distant failure rates in breast carcinoma and a “commonsense” approach. Cancer. 2001; 92: 2220–2227.
    Direct Link:
  • 27
    Harris E, Albert A. Survivorship analysis for clinical studies. New York: Dekker, 1991.
  • 28
    Perkins P, Cooksley CD, Cox JD. Breast cancer. Is ethnicity an independent prognostic factor for survival? Cancer. 1996; 78: 1241–1247.
    Direct Link:
  • 29
    Newman LA, Kuerer HM, Hunt KK, et al. Response to induction chemotherapy in black and white patients with locally advanced breast cancer. Breast J. 2000; 6: 242–246.
    Direct Link:
  • 30
    Brawley OW. Disaggregating the effects of race and poverty on breast cancer outcomes. J Natl Cancer Inst. 2002; 94: 471–473.
  • 31
    Fisher ER, Anderson S, Tan-Chiu E, Fisher B, Eaton L, Wolmark N. Fifteen-year prognostic discriminants for invasive breast carcinoma: National Surgical Adjuvant Breast and Bowel Project Protocol-06. Cancer. 2001; 91(8 Suppl ): 1679–1687.
    Direct Link:
  • 32
    Albain K, Unger J, Hutchins L, et al. Outcome of African Amercans on Southwest Oncology Group (SWOG) breast cancer adjuvant therapy trials. Paper presented at: San Antonio Breast Cancer Symposium, 2003; San Antonio, TX.
  • 33
    Chu KC, Tarone RE, Brawley OW. Breast cancer trends of black women compared with white women. Arch Fam Med. 1999; 8: 521–528.
  • 34
    Clegg LX, Li FP, Hankey BF, Chu K, Edwards BK. Cancer survival among US whites and minorities: a SEER (Surveillance, Epidemiology, and End Results) program population-based study. Arch Intern Med. 2002; 162: 1985–1993.
  • 35
    Klineberg SL. Houston's economic and demographic transformations: findings from the expanded 2002 Survey of Houston's Ethnic Communities. Houston: Rice University Press, 2002.
  • 36
    Klineberg SL. The Houston Area Survey 1982-Present. 2002. Available at http://cohesion.rice.edu/centersandinst/has/index.cfm.
View Full Article (HTML) Get PDF (165K)